Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia.
There are important interactions between prostatic tumours and bone. This study was designed to examine whether prostatic tissue can express bone inductive factors, in particular, the Bone Morphogenetic Proteins (BMPs). The polymerase chain reaction (PCR) has been used to screen for the expression of BMPs one to six in the prostatic tissue of patients with benign prostatic hyperplasia (BPH), non-metastatic prostatic adenocarcinoma and metastatic prostatic adenocarcinoma. BMPs were expressed in both benign and malignant prostate tissue and in the prostate tumour cell lines, PC3 and DU145. BMPs were also expressed in ocular melanoma tissue, a tissue which rarely metastasizes to bone. BMP-6 expression was detected in the prostate tissue of over 50% of patients with clinically defined metastatic prostate adenocarcinoma, but was not detected in non-metastatic or benign prostate samples or in ocular melanoma tissue. These findings suggest that the BMPs may play a role in the osteoinductive activity of prostate metastases and that the pattern of expression of BMPs may be important in the pathogenesis of osteoblastic metastases associated with prostate adenocarcinoma.
D000230:Adenocarcinoma / Q000737:chemistry*; D055398:Bone Morphogenetic Protein 3; D019485:Bone Morphogenetic Proteins; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000032:analysis*; D016133:Polymerase Chain Reaction; D011470:Prostatic Hyperplasia; D011471:Prostatic Neoplasms / Q000737:chemistry*; D011506:Proteins / Q000032:analysis*; D014407:Tumor Cells, Cultured
C525757:BMP3 protein, human; D055398:Bone Morphogenetic Protein 3; D019485:Bone Morphogenetic Proteins; D009363:Neoplasm Proteins; D011506:Proteins